|
|
Vaccine Detail
|
mRNA-based Personalized Cancer Vaccine NCI-4650 |
| Vaccine Information |
- Vaccine Name: mRNA-based Personalized Cancer Vaccine NCI-4650
- Target Pathogen: Cancer
- Target Disease: Cancer
- Manufacturer: Current Good Manufacturing Practice (cGMP) product by ModernaTX, Inc.
- Type: mRNA
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: neoantigens (NCT03480152), tumor-associated antigens (TAAs) (NCIT_C148239)
- Immunization Route: Intramuscular injection (i.m.)
- Description: This is a mRNA-based therapeutic personalized cancer vaccine (PCV) targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. Up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. The mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. (NCIT_C148239) Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. This mRNA vaccine might cause certain tumors to shrink. Immunogenic neoantigens and can predict for neoantigens binding the patient human leukocyte antigen (HLA) molecules from melanoma or epithelial cancer patients and use these epitopes for a personalized therapeutic messenger ribonucleic acid (mRNA) vaccine. (NCT03480152)
|
| Host Response |
|
|
| References |
NCIT_C148239: mRNA-based Personalized Cancer Vaccine NCI-4650 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148239]
NCT03480152: Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer [https://clinicaltrials.gov/study/NCT03480152]
|
|
